



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER 1. & TRADE	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
----------------------------------	-------------	-----------------------	------------------------

08/487,283 06/07/95 EVANS

M ALX-152.1CIP

SETH A FIDEL
ALEXION PHARMACEUTICALS
25 SCIENCE PARK
SUITE 360
NEW HAVEN CT 06511

0252/0825

DATE MAILED: 0000

NOTICE TO FILE MISSING PARTS OF APPLICATION FILING DATE GRANTED

08/25/95

An Application Number and Filing Date have been assigned to this application. However, the items indicated below are missing. The required items and fees identified below must be timely submitted **ALONG WITH THE PAYMENT OF A SURCHARGE** for items 1 and 3-6 only of \$ 1.00 for large entities or \$ 0.50 for small entities who have filed a verified statement claiming such status. The surcharge is set forth in 37 CFR 1.16(e).

If all required items on this form are filed within the period set below, the total amount owed by applicant as a ☐ large entity, ☐ small entity (verified statement filed), is \$ 800.

Applicant is given **ONE MONTH FROM THE DATE OF THIS LETTER, OR TWO MONTHS FROM THE FILING DATE** of this application, **WHICHEVER IS LATER**, within which to file all required items and pay any fees required above to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

1. ☒ The statutory basic filing fee is: ☒ missing ☐ insufficient. Applicant as a ☒ large entity ☐ small entity, must submit \$ 1.00 to complete the basic filing fee.

2. ☐ Additional claim fees of \$ _____ as a ☐ large entity, ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

3. ☒ The oath or declaration:

☒ is missing.

☐ does not cover the newly submitted items.

An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date is required.

4. ☐ The oath or declaration does not identify the application to which it applies. An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.

5. ☐ The signature(s) to the oath or declaration is/are: ☐ missing; ☐ by a person other than the inventor or a person qualified under 37 CFR 1.42, 1.43, or 1.47. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.

6. ☐ The signature of the following joint inventor(s) is missing from the oath or declaration:

_____ An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date, is required.

7. ☐ The application was filed in a language other than English. Applicant must file a verified English translation of the application and a fee of \$ _____ under 37 CFR 1.17(k), unless this fee has already been paid.

8. ☐ A \$ _____ processing fee is required since your check was returned without payment. (37 CFR 1.21(m)).

9. ☐ Your filing receipt was mailed in error because your check was returned without payment.

10. ☒ The application does not comply with the Sequence Rules. See attached Notice to Comply with Sequence Rules 37 CFR 1.821-1.825.

110 MG 11/28/95-08487283

1 201 375.00 CK

11. ☐ Other.

110 MG 11/28/95-08487283

1 205 65.00 CK

Direct the response to Box Missing Part and refer any questions to the Customer Service Center at (703) 308-1202.

A copy of this notice MUST be returned with the response.



Attorney Docket No.: ALX-152.1 CIP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark J. Evans, Louis A. Matis, Eileen Elliott Mueller, Steven H. Nye, Scott Rollins, Russell P. Rother, Jeremy P. Springhorn, Stephen P. Squinto, Thomas C. Thomas, and James A. Wilkins

Serial No.: 08/487,283

Filed: June 7, 1995

For: Methods and Compositions for the Treatment of Inflammatory Diseases

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, PRELIMINARY AMENDMENT AND DECLARATION

Certificate of Mailing

I hereby certify that this correspondence, along with any papers referred to as being attached or enclosed, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below.

Date Mailed: October 24, 1995

10/24/95
Date Signed

Seth A. Fidel, Ph.D.

Sir:

Responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on August 25, 1995, in the above identified application, applicants enclose a 3½" diskette containing a computer readable form of the Sequence Listing as well as a paper copy of the Sequence Listing.


Preliminary Amendment

Also responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on August 25, 1995, in the above identified application, please preliminarily amend the above referenced application by entering the enclosed substitute paper copy of the Sequence Listing into the application, replacing pages 97 to 191 of the application with attached pages 97 to 170, and renumbering the remaining pages in the application accordingly. The attached Sequence Listing contains no new matter, but includes corrected and updated general information.

Declaration under 37 C.F.R. §1.821(f)

I hereby declare that the material on the enclosed diskette is the same as the content of the enclosed substitute paper copy of the Sequence Listing, that this substitute Sequence Listing does not add any new matter to the application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,



Seth A. Fidel, Ph.D.
Reg. No. 38,449
Alexion Pharmaceuticals
25 Science Park, Suite 360
New Haven, CT 06511
(203) 776-1790

Date: 10/24/95

U.S.S.N. 08/487,283; Filed June 7, 1995
Response To Notice To Comply With Requirements For Patent Applications
Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures,
Preliminary Amendment And Declaration

COMPLETION OF FILING REQUIREMENTS AND
PETITION AND FEE FOR EXTENSION OF TIME
PURSUANT TO 37 CFR 1.136(a)

This is in response to the Notice to File Missing Parts of Application - Filing Date Granted, mailed August 25, 1995, a copy of which is enclosed herewith.

Enclosed herewith please find:

a copy of the "Notice to File Missing Parts of Application - Filing Date Granted";

an original signed declaration and power of attorney;

a copy of the Sequence Listing in computer readable form (WORDPERFECT 3.0 text file on 1.4 megabyte MACINTOSH formatted 3½" diskette) as required by 37 CFR 1.821(e);

a substitute paper copy of the "Sequence Listing";

a preliminary amendment directing the entry of the substitute paper copy of the "Sequence Listing" into the specification, and a declaration that the content of the paper and computer readable copies are the same and include no new matter;

check No. 16094 for \$430.00.

check No. 16308 for \$65.00.

REMARKS

Pursuant to 37 CFR 1.136(a), this is a petition for an extension of time to respond to the Notice to File Missing Parts of Application - Filing Date Granted, mailed August 25, 1995, for a period of one month. With the extension, the response will be due on October 25, 1995. As detailed below, the enclosed checks include \$55.00 for a Patent Extension Fee for a small entity under 37 CFR §1.17(a). No additional extension of time is believed to be necessary for this submission, but if an additional extension of time is required, applicants request that this be considered a petition therefor. The Commissioner is hereby authorized to charge any fees which may be required for such an additional extension to Deposit Account No. 01-0483.

No signed declaration or oath was filed and enclosed is the original signed declaration for this application.

No copy of the sequence listing in computer readable form was submitted. Enclosed herewith is: a substitute paper copy of the Sequence Listing; a copy of the Sequence Listing in computer readable form (WORDPERFECT 3.0 text file on 1.4 megabyte MACINTOSH formatted 3½" diskette) as required by 37 CFR 1.821(e); a preliminary amendment directing the entry of the substitute paper copy of the Sequence Listing into the specification; and a declaration that the content of the paper and computer readable copies are the same and include no new matter;

This application is on behalf of a small entity and a verified statement is:

() already filed

(X) attached

The filing fee has been calculated as shown below:


Basic Fee	\$375.00
Surcharge fee for late payment	
of filing fee and filing of declaration	\$65.00
Patent Extension Fee under 37 CFR §1.17(a)	<u>\$55.00</u>
Total fees	\$495.00

Two checks, one in the amount of \$430.00 and one in the amount of \$65.00 are attached, for a total of \$495.00. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 01-0483.

Respectfully submitted,

Date:

10/24/95


Seth A. Fidel, Ph.D.
Reg. No. 34,899
Alexion Pharmaceuticals, Inc.
25 Science Park, Suite 360
New Haven, CT 06511
(203) 776-1790